Connect with us

Technology

Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis

Published

3 years ago

on

NASHVILLE, June 28, 2023 /PRNewswire/ — Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. This milestone marks a significant step forward in the development of advanced treatment options for individuals affected by this chronic and debilitating skin condition.

The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of safety.

Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1). Despite the availability of various treatment options, there remains an unmet need for more effective and safer therapies. With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis.

The Phase 2b clinical trial will continue to build upon a recent trial that has evaluated the safety and efficacy of AMTX-100 CF3 in a larger cohort of adult patients that has shown favorable efficacy bypassing the need for rescue steroid treatment. This randomized, double-blind, placebo-controlled study will be conducted at 8-10 clinical sites across the country. This study is seeking 60 participants to generate a 1:1 ratio between placebo and active arms of the study. The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of treatment safety.

This clinical trial will include a 28-day treatment period with twice daily treatment and a 2-week follow-up assessment post-treatment to determine therapeutic efficacy. In addition, participants will receive a topical emollient 2-weeks prior to trial to exclude participants who may be impacted by a placebo effect. Precision medicine techniques will also be used to assess changes in the expression of genes involved in inflammation.

“We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3,” said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. “At Amytrx, we are committed to developing innovative therapies that can make a meaningful difference in the lives of patients. This trial represents a crucial step towards bringing a safe and targeted treatment option to adults suffering from atopic dermatitis, in addition to other chronic inflammatory skin diseases such as psoriasis, vitiligo, lupus, graft vs. host, and more.”

Amytrx Therapeutics has invested years of research and development into the creation of AMTX-100 CF3. This unique topical formulation of their anti-inflammatory peptide has shown promising results in preclinical and clinical studies. AMTX-100 CF3 utilizes a novel untapped intracellular target to control inflammation. The company believes that AMTX-100 CF3 has the potential to provide durable relief, enhance quality of life, and minimize the burden of this chronic condition with a revolutionary approach that interacts with a key checkpoint in the initiation of inflammation.

The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway. Eligible adults interested in participating or learning more about the trial are encouraged to visit the ClinicalTrials.Gov listing # NCT04313400 or visit Amytrx Therapeutics’ website at www.amytrx.com. The company welcomes collaboration with research institutions that wish to contribute to advancing the knowledge and treatment of other inflammatory skin disorders.

The current topical formulation of AMTX-100 CF3 being studied in the Phase 2b clinical trial provides an example of the various formulations available for novel anti-inflammatory peptide AMTX-100. Amytrx Therapeutics is actively exploring other delivery methods to cater to the diverse needs of patients across a variety of inflammatory diseases. These formulations include oral, injectable, nasal spray, and other options. This comprehensive approach underscores Amytrx Therapeutics’ commitment to developing a range of therapeutic options that can effectively target inflammation and provide additional treatment strategies.

About Amytrx Therapeutics

Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world’s most debilitating diseases. For further information, please visit www.amytrx.com. 

Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 52. https://doi.org/10.1186/s13223-018-0281-6

View original content to download multimedia:https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

SOURCE Amytrx Therapeutics

Related Topics:
Continue Reading

Technology

Linker Vision Announces ESG Agent to Help Cities Plan More Sustainable Urban Environments

Published

32 minutes ago

on

October 19, 2026

By

BERLIN, Oct. 19, 2026 /PRNewswire/ — Linker Vision announced a new ESG AI agent designed to help urban planners evaluate sustainability initiatives and make more informed decisions. By combining environmental predictions with AI reasoning, the agent assesses urban heat and shade coverage to guide tree planting and greenery management, supporting cities’ climate adaptation goals. 

Turning sustainability goals into practical decisions

Linker Vision is working with MVRDV, the Dutch architecture and urban design firm, to explore how AI can help cities assess potential interventions before making changes in the real world. MVRDV contributed scientific data, shaped the evaluation criteria the agent uses to assess planning options, and tested the ESG agent during development.

An initial application focuses on urban forests. Linker Vision is collaborating with MVRDV on a digital twin that supports predictions of urban heat island effects and shade coverage. In the pilot, the agent identifies heat hotspots, selects suitable tree species and simulates the results, projecting that shade coverage could rise from 15.7% to more than 50% within 15 years.

Building on this pilot, the approach allows a shared digital twin to support multiple planning needs, including climate adaptation and disaster resilience. Urban forest planning is available today, and going forward, the city digital twin is designed to serve as a common foundation that government agencies can build on for additional applications, such as analyzing pedestrian flows and preparing venues for major sporting events.

How it works

The workflow combines a digital twin built using 3D Gaussian Splatting with NVIDIA accelerated computing and AI technologies. NVIDIA Omniverse libraries and OpenUSD have been implemented to unify city, tree and environmental data into a single scene, while NVIDIA Nemotron reasoning models let users run planting scenarios and optimize shade through natural language. NVIDIA Metropolis Blueprint for video search and summarization (VSS) and Cosmos open world foundation model help interpret video and understand real-world conditions.

In practice, a planner asks the agent where new trees would best reduce street-level heat. The agent tests planting options and simulates shade and temperature over a 15-year timespan in minutes, and planners review the recommended plan before an urban heat hotspot project moves forward.

Designing for future generations

“Every decision about a city shapes how future generations will live,” said Paul Shieh, founder and CEO of Linker Vision. “By connecting real-world understanding with simulation and AI reasoning, we want to help cities explore what is possible and make better choices for people and the planet.”

View original content:https://www.prnewswire.co.uk/news-releases/linker-vision-announces-esg-agent-to-help-cities-plan-more-sustainable-urban-environments-302911111.html

Continue Reading

Technology

Global Startup EXPO and Nippon Startup Awards 2026: METI Showcases Japan’s Deep-tech Results

Published

32 minutes ago

on

October 19, 2026

By

– GSE2026 Connects Global Venture Capitalists with Japanese Startups; Nippon Startup Awards 2026 Honors Startups Turning Innovation into Industry –

TOKYO, Oct. 19, 2026 /PRNewswire/ — From September to October 2026, the Ministry of Economy, Trade and Industry (hereinafter “METI”) held the Global Startup EXPO 2026 (hereinafter “GSE2026”) and the Nippon Startup Awards 2026, highlighting the strength and growth of Japan’s startup ecosystem. GSE2026 brought together top-tier investors, visionary startups, corporations, and key ecosystem participants from Japan and around the globe. Separately, the Nippon Startup Awards 2026 recognized remarkable innovations demonstrating Japan’s growing capacity to transform breakthrough deep-tech into real-world industrial solutions.

Expo and Awards Logos:
https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202610137787/_prw_PI1fl_JPI1sgRq.png 

Global Startup EXPO 2026 Recap

In Session: https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202610137787/_prw_PI2fl_AyG90Gzn.png 

Held in Osaka from October 5 to 7, GSE2026 welcomed more than 10,000 visitors and featured over 50 conference sessions. The event served as a premier global hub, generating vital business matchmaking sessions and creating unparalleled opportunities for global investors and Japanese startups to explore strategic investments and collaborations. A major highlight of the event was the participation of prominent industry figures, including Ben Horowitz, co-founder of Andreessen Horowitz (a16z), and Andy Rubin, co-founder of Android. Their presence underscored the increasing global interest in Japan’s dynamic tech ecosystem. Building upon this remarkable success, METI is pleased to announce that the Global Startup EXPO is planned to be held again next year.

Nippon Startup Awards 2026 Overview

Group Photo: https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202610137787/_prw_PI3fl_MNvb1svB.jpg 

In a separate initiative, the 2026 Nippon Startup Awards celebrated exceptional entrepreneurial achievements, recognizing 10 outstanding companies for their innovation and impact. This press release proudly highlights two exceptional winners whose pioneering technologies are actively addressing major industrial and societal challenges both in Japan and internationally.

– Mujin (Prime Minister’s Award): Mujin was recognized for becoming the first company to globally commercialize complex motion-planning technology, an ambitious feat considered practically impossible for 50 years. By successfully developing its proprietary MujinMI technology, the company enables the automation of complex logistics and manufacturing operations. This advancement offers a highly effective solution to pressing global labor shortages.

– Regional Fish (Minister of Economy, Trade and Industry Award): Regional Fish was recognized for its pioneering use of genome-editing technology in aquaculture. Through its innovative approach, the company has shortened aquatic breeding cycles from approximately 30 years to just two or three years. This advancement contributes significantly to sustainable solutions for global food challenges and the revitalization of regional fisheries.

Further Information

To explore comprehensive insights from the recent global summit, please access the following link:
https://global-startup-expo.com/en/?utm_source=prwire&utm_medium=referral&utm_campaign=20260914&utm_content=en_url＿

For the full list of recognized companies, please visit: https://www.meti.go.jp/english/press/2026/09/20260925002.html 

View original content:https://www.prnewswire.com/news-releases/global-startup-expo-and-nippon-startup-awards-2026-meti-showcases-japans-deep-tech-results-302912264.html

SOURCE Ministry of Economy, Trade and Industry (METI)

Continue Reading

Technology

PingPong continues international growth, expands into Iberia through strategic partnership with Getnet

Published

32 minutes ago

on

October 19, 2026

By

LONDON and MADRID, Oct. 19, 2026 /PRNewswire/ — PingPong , the intelligent payments infrastructure for global growth, today announces a strategic partnership with Getnet, the leading AI-payments company, part of Santander Group, to expand access to its financial infrastructure across Iberia.

The collaboration brings together two established payments businesses to deliver a stronger payment capability in the region and a simple, streamlined solution for global businesses looking to expand operations in Iberia.

Aaron Xu, General Manager, Europe and Americas at PingPong , said: “Iberia is one of Europe’s most valuable commerce markets, and the 750,000+ businesses in our network want to operate there on payment infrastructure they already trust. Our move into Iberia is the latest step in an ongoing global expansion, driven by rising customer demand and sustained investment in our international growth.”

Fabrice Mendez, Global Head of Partnerships at Getnet , said: “This partnership represents another important milestone in Getnet’s strategy to expand our open-market business across Europe while strengthening the connections between Iberia and one of the world’s fastest-growing commerce ecosystems. By combining PingPong’s strong presence across Asia with Getnet’s leadership in Europe and Latin America, we are creating new opportunities for international merchants to grow with a seamless and trusted payment experience.”

About PingPong

Founded in 2015, PingPong is a global cross-border B2B payments platform supporting over 750,000 businesses across more than 200 countries. The company annually processes over $300bn and holds 80+ financial licences worldwide. PingPong operates from 44 offices across 18 countries.

For more information, visit www.pingpongx.com.

About Santander Getnet

In 2025, Getnet processed over €238 billion across 10.5 billion transactions, serving 1.2 million clients. The company ranks as the largest acquirer in Latin America by purchase volume, and among the top 10 globally. Getnet operates across Brazil (as an e-commerce leader), Mexico, Chile, Argentina, Uruguay, Spain, and Portugal.

View original content:https://www.prnewswire.co.uk/news-releases/pingpong-continues-international-growth-expands-into-iberia-through-strategic-partnership-with-getnet-302911506.html

Continue Reading

Trending